Skip to main content
. Author manuscript; available in PMC: 2015 Dec 21.
Published in final edited form as: Br J Haematol. 2013 Jun 21;162(4):517–524. doi: 10.1111/bjh.12436

Figure 1. Pharmacokinetics of oral rigosertib.

Figure 1

A. Three patients were treated with single escalating weekly doses of oral rigosertib to determine pharmacokinetics. Data are shown for one patient as the profiles were similar for all 3 patients. Following a single oral dose (fasting) the rigosertib pharmacokinetics were linear and dose-proportional over the dose range of 70–700 mg. B. Bioavailability of oral rigosertib (560 mg), under fasting and fed conditions, was compared to that of intravenously administered rigosertib (800 mg/m2/24 h) in 12 patients in the expansion cohort.